2024年6月最新影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | BREAST CANCER RESEARCH AND TREATMENT BREAST CANCER RES TR （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.7
50人评分
我要评分
声誉 8.7 影响力 6.5 速度 9.7 | |||||||||||||||||||||
| 期刊ISSN | 0167-6806 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1573-7217 | |||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 3 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2024年3月26日：2.989 | |||||||||||||||||||||
| 2023-2024自引率 | 6.70%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 3.9 | |||||||||||||||||||||
| JCI期刊引文指标 | 0.73 | |||||||||||||||||||||
| h-index | 139 | |||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://www.springer.com/10549 | |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/brea | |||||||||||||||||||||
| 作者指南网址 | https://www.springer.com/10549/submission-guidelines | |||||||||||||||||||||
| 期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足BREAST CANCER RESEARCH AND TREATMENT的语言要求，还能让BREAST CANCER RESEARCH AND TREATMENT编辑和审稿人得到更好的审稿体验，让稿件最大限度地被BREAST CANCER RESEARCH AND TREATMENT编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013 | |||||||||||||||||||||
| 出版商 | Springer US | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||||||
| 出版年份 | 1981 | |||||||||||||||||||||
| 年文章数 | 328点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 31.77% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.90% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0167-6806%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均1月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约25% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在BREAST CANCER RESEARCH AND TREATMENT顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial Author: Xie, Xiao-Feng; Zhang, Qiu-Yi; Huang, Jia-Yi; Chen, Li-Ping; Lan, Xiao-Feng; Bai, Xue; Song, Lin; Xiong, Shui-Ling; Guo, Si-Jia; Du, Cai-Wen Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 1, pp. 93-101. DOI: 10.1007/s10549-022-06770-6 PubMed DOI |
| 2. | Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis Author: Cao Lu; Yang Yang; Li Lingmei; Huang Qiujuan; Guo Qianru; Qi Lisha; Cao Wenfeng; Niu Yun; Zhang Peisen Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 1, pp. 71-82. DOI: 10.1007/s10549-022-06788-w PubMed DOI |
| 3. | Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population Author: Chen, Ruixian; Qi, Yana; Huang, Ya; Liu, Weijing; Yang, Ruoning; Zhao, Xin; Wu, Yunhao; Li, Qintong; Wang, Zhu; Sun, Xin; Wei, Bing; Chen, Jie Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 1, pp. 189-200. DOI: 10.1007/s10549-022-06781-3 PubMed DOI |
| 4. | Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis Author: Yang, Zhengyan; Xu, Hongyun; Yang, Yupo; Duan, Chaoqun; Zhang, Pai; Wang, Yang; Fu, Kai; Shen, Yonghong; Xu, Marvin Xuejun Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 2, pp. 255-267. DOI: 10.1007/s10549-022-06790-2 PubMed DOI |
| 5. | Correlation analysis between shear-wave elastography and pathological profiles in breast cancer Author: Li, Junnan; Sun, Bo; Li, Yanbo; Li, Shuang; Wang, Jiahui; Zhu, Ying; Lu, Hong Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 2, pp. 269-276. DOI: 10.1007/s10549-022-06804-z PubMed DOI |
| 6. | Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer Author: Wang, Huiling; Sheng, Xiaonan; Yan, Tingting; Xu, Yaqian; Wang, Yaohui; Lin, Yanping; Zhang, Jie; Ye, Yumei; Xu, Shuguang; Zhou, Liheng; Yin, Wenjin; Lu, Jinsong Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 2, pp. 343-354. DOI: 10.1007/s10549-022-06791-1 PubMed DOI |
| 7. | Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study Author: Xu, Binghe; Li, Wei; Zhang, Qingyuan; Li, Qiao; Wang, Xiaojia; Li, Huiping; Sun, Tao; Yin, Yongmei; Zheng, Hong; Feng, Jifeng; Zhu, Huaqi; Siddiqui, Asna; Macharia, Harrison; Knott, Adam Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 3, pp. 503-513. DOI: 10.1007/s10549-022-06775-1 PubMed DOI |
| 8. | Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up Author: Gao, Song-lin; Wang, Ding-yuan; Wang, Xi; Zhang, Bo; Du, Feng; Ju, Jie; Yue, Jian; Kang, Yi-kun; Wang, Xue; Xu, Bing-he; Yuan, Peng Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 3, pp. 569-582. DOI: 10.1007/s10549-022-06762-6 PubMed DOI |
| 9. | Malignant phyllodes tumors of the breast: the malignancy grading and associations with prognosis Author: Liu, Junjun; Li, Fangfang; Liu, Xuejing; Lang, Ronggang; Liang, Rong; Lu, Hong Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10549-023-06933-z PubMed DOI |
| 10. | Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer Author: Liu, Yu; Wang, Ying; Feng, Senwen; Xu, Zeyan; Yao, Mengxia; Huang, Xiaomei; Li, Pinxiong; Wu, Lei; Liu, Chunling; Chen, Xin; Liang, Changhong; Liu, Zaiyi Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 3, pp. 515-523. DOI: 10.1007/s10549-022-06817-8 PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
